Posted by admin in 
A drug given to kidney cancer patients called sorafenib, also known as Nexavar, has shown the ability to extend the lives of liver cancer patients.
The drug, according to researchers from the New York Mount Sinai School of Medicine extended the lives of liver cancer patients by as much as 44% longer than those given a dummy pill.
Furthermore, the patients given Nexavar also experienced slower cancer growth than the patients given the placebo.
“This is the first time that we’ve had an effective systemic treatment for liver cancer,” Dr. Josep Llovet, the director of liver cancer research at Mount Sinai and lead author of the study, said in a statement.
Patients given the drug lived on average an additional 10 months, opposed to just over 7 months for the placebo group.
The findings are published in the New England Journal of Medicine.
